When It Comes To Competing, The Academy Just Says No

The National Academy of Sciences has operated NSF's graduate fellowship program since 1952. But it has never had to compete for the contract, now worth close to $2 million annually. That's because of the academy's own rule that prohibits it from doing any work for the government if it first must submit a bid and be chosen over several competitors. "We can't compete," says Frank Press, academy president. "If an agency accepts other bids, then we can't do the work. The rule stems from our 1863

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"We can't compete," says Frank Press, academy president. "If an agency accepts other bids, then we can't do the work. The rule stems from our 1863 charter [issued by Congress], and I certainly don't want to be the one to break with that tradition."

According to Press, the academy was created to provide a unique consultative service to Congress and the executive branch on matters of science and technology. The academy would be violating that charge, he explains, if it were to become involved in activities that could be performed equally well by another outside organization, he says.

A second reason involves money. Competitions are won by the best of the lowest-priced bidders, Press says, and the academy does not want to participate in any activity that places such importance on the price of the service rendered. "Submitting a bid would force us to look at the bottom line, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies